AMNEAL PHARMACEUTICALS, INC. Inventory Write-down
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Inventory Write-down of $44.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2026-06-30 was $31.60M, a 114.08% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2026-03-31 was $13.35M, a 43.58% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2025-12-31 was $26.64M, a 19.16% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. inventory write-down for the quarter ending 2025-09-30 was $20.89M, a 5.53% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. inventory write-down for fiscal 2025 was $85.96M, a 10.97% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. inventory write-down for fiscal 2024 was $96.56M, a 29.29% increase from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. inventory write-down for fiscal 2023 was $74.69M, a 46.17% increase from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. inventory write-down for fiscal 2022 was $51.10M, a 6.52% decline from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $44.96M 10-Q · filed 2026-08-06 | $71.59M derived: sum of 3 quarters · filed 2026-08-06 | $92.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $13.35M 10-Q · filed 2026-05-07 | $39.99M derived: sum of 2 quarters · filed 2026-05-07 | $60.88M derived: sum of 3 quarters · filed 2026-05-07 | $75.65M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $26.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $47.53M derived: sum of 2 quarters · filed 2026-02-27 | $62.29M derived: sum of 3 quarters · filed 2026-08-06 | $85.96M 10-K · filed 2026-02-27 |
| 2025-09-30 | $20.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $35.66M derived: sum of 2 quarters · filed 2026-08-06 | $59.33M 10-Q · filed 2025-11-06 | $92.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $14.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $38.43M 10-Q · filed 2026-08-06 | $71.38M derived: sum of 3 quarters · filed 2026-08-06 | $93.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $23.67M 10-Q · filed 2026-05-07 | $56.62M derived: sum of 2 quarters · filed 2026-05-07 | $78.73M derived: sum of 3 quarters · filed 2026-05-07 | $97.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $32.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $55.06M derived: sum of 2 quarters · filed 2026-02-27 | $73.64M derived: sum of 3 quarters · filed 2026-02-27 | $96.56M 10-K · filed 2026-02-27 |
| 2024-09-30 | $22.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $40.69M derived: sum of 2 quarters · filed 2025-11-06 | $63.61M 10-Q · filed 2025-11-06 | $81.66M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $18.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $41.49M 10-Q · filed 2025-08-07 | $59.54M derived: sum of 3 quarters · filed 2026-02-27 | $74.37M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $22.92M 10-Q · filed 2025-05-07 | $40.97M derived: sum of 2 quarters · filed 2026-02-27 | $55.80M derived: sum of 3 quarters · filed 2026-02-27 | $72.41M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $18.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $32.88M derived: sum of 2 quarters · filed 2026-02-27 | $49.48M derived: sum of 3 quarters · filed 2026-02-27 | $74.69M 10-K · filed 2026-02-27 |
| 2023-09-30 | $14.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $31.43M derived: sum of 2 quarters · filed 2024-11-12 | $56.64M 10-Q · filed 2024-11-12 | $78.85M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $16.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $41.81M 10-Q · filed 2024-08-09 | $64.02M derived: sum of 3 quarters · filed 2025-02-28 | $75.15M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $25.20M 10-Q · filed 2024-05-08 | $47.42M derived: sum of 2 quarters · filed 2025-02-28 | $58.55M derived: sum of 3 quarters · filed 2025-02-28 | $72.72M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $22.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $33.35M derived: sum of 2 quarters · filed 2025-02-28 | $47.52M derived: sum of 3 quarters · filed 2025-02-28 | $51.10M 10-K · filed 2025-02-28 |
| 2022-09-30 | $11.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $25.31M derived: sum of 2 quarters · filed 2023-11-09 | $28.88M 10-Q · filed 2023-11-09 | $44.25M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $14.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $17.75M 10-Q · filed 2023-08-08 | $33.12M derived: sum of 3 quarters · filed 2024-03-14 | $46.60M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $3.58M 10-Q · filed 2023-05-09 | $18.95M derived: sum of 2 quarters · filed 2024-03-14 | $32.43M derived: sum of 3 quarters · filed 2024-03-14 | $42.22M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $15.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $28.86M derived: sum of 2 quarters · filed 2024-03-14 | $38.64M derived: sum of 3 quarters · filed 2024-03-14 | $54.66M 10-K · filed 2024-03-14 |
| 2021-09-30 | $13.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $23.27M derived: sum of 2 quarters · filed 2022-11-07 | $39.29M 10-Q · filed 2022-11-07 | $58.33M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $9.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $25.80M 10-Q · filed 2022-08-08 | $44.84M derived: sum of 3 quarters · filed 2023-03-03 | $66.33M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $16.02M 10-Q · filed 2022-05-06 | $35.06M derived: sum of 2 quarters · filed 2023-03-03 | $56.55M derived: sum of 3 quarters · filed 2023-03-03 | $76.06M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $19.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $40.53M derived: sum of 2 quarters · filed 2023-03-03 | $60.04M derived: sum of 3 quarters · filed 2023-03-03 | $75.24M 10-K · filed 2023-03-03 |
| 2020-09-30 | $21.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $41.00M derived: sum of 2 quarters · filed 2021-11-08 | $56.20M 10-Q · filed 2021-11-08 | $70.60M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $19.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $34.71M 10-Q · filed 2021-08-09 | $49.11M derived: sum of 3 quarters · filed 2022-03-01 | $66.54M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $15.20M 10-Q · filed 2021-05-07 | $29.60M derived: sum of 2 quarters · filed 2022-03-01 | $47.03M derived: sum of 3 quarters · filed 2022-03-01 | $81.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $14.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $31.84M derived: sum of 2 quarters · filed 2022-03-01 | $66.59M derived: sum of 3 quarters · filed 2022-03-01 | $82.25M 10-K · filed 2022-03-01 |
| 2019-09-30 | $17.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $52.19M derived: sum of 2 quarters · filed 2020-11-06 | $67.84M 10-Q · filed 2020-11-06 | $91.63M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $34.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $50.41M 10-Q · filed 2020-08-06 | $74.19M derived: sum of 3 quarters · filed 2021-03-01 | $77.52M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $15.65M 10-Q · filed 2020-05-11 | $39.43M derived: sum of 2 quarters · filed 2021-03-01 | $42.76M derived: sum of 3 quarters · filed 2021-03-01 | $57.34M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $23.78M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $27.11M derived: sum of 2 quarters · filed 2021-03-01 | $41.69M derived: sum of 3 quarters · filed 2021-03-01 | $44.54M 10-K · filed 2021-03-01 |
| 2018-09-30 | $3.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $17.91M derived: sum of 2 quarters · filed 2019-11-07 | $20.75M 10-Q · filed 2019-11-07 | $23.02M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $14.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $17.43M 10-Q · filed 2019-08-05 | $19.69M derived: sum of 3 quarters · filed 2020-03-02 | $19.15M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $2.85M 10-Q · filed 2019-05-09 | $5.11M derived: sum of 2 quarters · filed 2020-03-02 | $4.57M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $1.72M derived: sum of 2 quarters · filed 2020-03-02 | $3.77M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$537.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $1.51M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $2.05M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $9.23M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |